second-line therapy

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

A recent phase II trial demonstrates lenvatinib’s efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

Efficacy of Liposomal Irinotecan Plus 5-FU/LV in Previously Treated Biliary Tract Cancer: Insights from Pooled NIFTY and NALIRICC Trials